U.S. Capital Wealth Advisors LLC Has $816,000 Stock Holdings in Axon Enterprise, Inc (NASDAQ:AXON)

U.S. Capital Wealth Advisors LLC cut its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 23.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,551 shares of the biotechnology company's stock after selling 481 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Axon Enterprise were worth $816,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Capital World Investors raised its holdings in shares of Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after acquiring an additional 841,772 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after acquiring an additional 812,337 shares during the last quarter. Norges Bank acquired a new position in shares of Axon Enterprise in the fourth quarter worth $482,081,000. GQG Partners LLC acquired a new position in shares of Axon Enterprise in the fourth quarter worth $478,349,000. Finally, GAMMA Investing LLC raised its holdings in shares of Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after acquiring an additional 763,431 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Performance

AXON traded up $20.64 during trading on Monday, reaching $750.26. 535,497 shares of the company were exchanged, compared to its average volume of 707,609. The stock has a market cap of $58.41 billion, a P/E ratio of 181.22, a PEG ratio of 83.99 and a beta of 1.29. The firm has a 50 day moving average of $752.67 and a 200 day moving average of $641.14. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. Axon Enterprise, Inc has a 52 week low of $279.02 and a 52 week high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm's revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.15 EPS. On average, sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXON has been the subject of a number of analyst reports. Bank of America boosted their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. The Goldman Sachs Group boosted their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Needham & Company LLC increased their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Barclays raised their price target on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Finally, Wolfe Research started coverage on Axon Enterprise in a research note on Monday, July 7th. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Insider Activity at Axon Enterprise

In other news, President Joshua Isner sold 9,905 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the sale, the president owned 298,809 shares in the company, valued at $220,530,006.27. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the sale, the chief executive officer owned 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,642 shares of company stock worth $30,500,428 in the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.